Opnurasib

**Semantic type:** Pharmacologic Substance

**Definition:** An inhibitor of the oncogenic KRAS substitution mutation, G12C, with potential antineoplastic activity. Upon administration, opnurasib selectively targets the KRAS G12C mutant and inhibits KRAS G12C mutant-dependent signaling. KRAS, a member of the RAS family of oncogenes, serves an important role in cell signaling, division and differentiation. Mutations of KRAS may induce constitutive signal transduction leading to tumor cell growth, proliferation, invasion, and metastasis.

**Synonyms:** - JDQ 443 - JDQ-443 - JDQ443 - KRAS G12C Inhibitor JDQ443 - NVP-JDQ-443 - OPNURASIB